This issue of Recent Results in Cancer Research presents a comprehensive review of current understanding of chromosomal instability in cancer and of strategies to use this information for better treatment of patients with cancer. Cancer is a disease of the chromosomes, and chromosomal instability in cancer disrupts gene function by either inactivating tumor suppressor genes or activating growth-promoting oncogenes. The chromosomal basis for these aberrations is either translocations, which change the integrity of genes, or abnormal numbers of chromosomes, a condition referred to as aneuploidy, which results in abnormal gene expression levels. Such structural or numerical chromosomal aberrations are specific for distinct tumor entities. The degree of chromosomal instability and the degree of intratumor heterogeneity have profound consequences for disease outcome and for therapeutic stratification.

This issue of Surgical Oncology Clinics of North America, edited by Thomas Weber, MD, is devoted to Genetic Testing in Surgical Oncology. Articles in this issue include: The Critical Importance of Timely Genetic Testing; Securing and Documenting Cancer Family History in the Age of the Electronic Medical Record; Cancer Family Registries: Vital Tools for Patient Management and Cancer Genetics Translational Research; The Genetics of Breast Cancer; The Genetics of Colorectal Cancer: HNPCC, FAP MYH, and Hamartomatous Syndromes Including Peutz-Jeghers and Jevenile Polyposis; Hereditary Gastric Cancer Syndromes; Hereditary Pancreatic Cancer Syndromes; Hereditary Melanoma: Genetics and Multidisciplinary Management; Multiple Endocrine Neoplasia: Genetics and Clinical Management; Sequence Variants of Uncertain Significance (VUS): What To Do When Genetic Testing Results Are Not Definitive; Confidentiality and the Risk of Genetic Discrimination: What Surgeons Need to Know; and A Certified Genetic Counselor: A Crucial Clinical Resource in the Management of Patients with Suspected Hereditary Solid Tumor Syndromes.

Drs. Robert J. Lewandowski and Matthew S. Davenport have assembled an expert panel of authors on the topic of Interventional Radiology. Articles will include: Abdominal Biopsy: Technical and Clinical Considerations; Intra-arterial Therapies for Liver Masses; Liver Ablation: Best Practice; Renal Intervention; Imaging (Findings) after Intervention; Assessing Imaging Response to Therapy; Liver Masses: Imaging Evaluation in Non-cirrhotics; Imaging in Cirrhotics: Current Evidence; Renal Masses: Imaging Evaluation; Adrenal Imaging/Intervention; The Pancreas; and more!

Cancers of the larynx, while survival outcomes increase, result in massive treatment damage from radiation and surgery. Patients often lose ability to speak and to eat. Preserving the larynx is a fine balance of cancer eradication, life extension, and quality of life. This issueof Otolaryngologic Clinics led by Dr Babak Sadoughi should be of interest to Otolaryngologists, Oncologists, Radiologists, and Speech Therapists. The issue approach reaches all the most important aspects of diagnosing and treating the patient with laryngeal cancer with a focus on preserving the voice in early laryngeal cancer and preserving and restoring function in advanced laryngeal cancer. Topics include: Functional Anatomy and Oncological Barriers of the Larynx; Evaluation of the Dysphonic Patient; Role of Advanced Laryngeal Imaging in Glottic Cancer; Laryngeal Function after Radiation Therapy; Management of Dysphonia after Radiation Therapy; Contemporary Surgical Management of Early Glottic Cancer; Voice Prognosis after Transoral Laser Microsurgery of the Larynx; Voice Rehabilitation after Transoral Laser Microsurgery of the Larynx; Quality of Life after Conservation Surgery for Laryngeal Cancer; Salvage Conservation Surgery of the Larynx; Airway Preservation in Ablative Laryngeal Surgery; Voice Restoration after Total Laryngectomy. A special article for Residents, written by a Resident, emphasizes essential "take home messages" for laryngeal function preservation diagnosis and treatment.

This book discusses cancers and the resurgence of public interest in plant-based and herbal drugs. It also describes ways of obtaining anti-cancer drugs from plants and improving their production using biotechnological techniques. It presents methods such as cell culture, shoot and root culture, hairy root culture, purification of plant raw materials, genetic engineering, optimization of culture conditions as well as metabolic engineering with examples of successes like taxol, shikonin, ingenol mebutate and podophylotoxin. In addition, it describes the applications and limitations of large-scale production of anti-cancer compounds using biotechnological means. Lastly, it discusses future economical and eco-friendly strategies for obtaining anti-cancer compounds using biotechnology.

This issue of Hematology/Oncology Clinics, guest edited by Dr. F. Stephen Hodi, is devoted to Melanoma. Articles in this issue include: The current state of Melanoma; Understanding the Biology of Melanoma Development and Therapeutic Implications; Surgical Management of Melanoma; Targeted Therapies for Cutaneous Melanoma; Treatments for Non-cutaneous Melanoma; Resistant Mechanisms and Therapeutic Implications; The Role of the Immune System in Melanoma Development and Treatment; Vaccines and Melanoma; IL-2, Interferon, and Cytokines; Immune Checkpoint Blockade; Adjuvant Treatments, Chance for Cure in Melanoma; and Combinatorial Approach to Treatment of Melanoma.

The Editors for this 2-part issue of Otolaryngologic Clinics, Dr George Wanna and Dr Matthew Luke Carlson, envisioned a publication that reviews the evaluation and management of common ear and lateral skull base tumors. Intended audience includes Otologists, Neurotologists, General otolaryngologists and Neurosurgeons alike. The development of management of lateral skull base tumors has been rapid, in the past 40 years there has been a tremendous shift toward conservative therapy for benign lesions. Focused chapters review specific pathologies plus a chapter focused on stereotactic radiotherapy. Topics written by reputed leaders in the field of Otology and skull base tumors include: Imaging of temporal bone lesions; Squamous cell carcinoma of the temporal bone; Glomus tympanicum; Adenomatous tumors of the middle ear; Intralabyrinthine schwannomas; Vestibular schwannoma; Neurofibromatosis2 (including ABI and CI); Non-schwannoma tumors of the CPA; Glomus jugulare; Endolymphatic sac tumors; Non-paraganglioma jugular foramen tumors; Primary tumors of the facial nerve; Cholesterol granuloma and other petrous apex lesions; Stereotactic radiosurgery for tumors of the lateral skull base; Pediatric temporal bone malignancy; and Historical perspective on evolution in management of lateral skull base tumors.

Cancer Screening and Genetics is reviewed extensively in this important Surgical Clinics of North America issue. Articles include: Cancer Genetics and Implications for Clinical Management; Epigenetics and Cancer; Screening and Early Detection of Cancer: Successes and Failures; Screening for Lung Cancer; Screening for Breast Cancer; Viral Hepatitis and Hepatocellular Cancer: How Should Patients Be Screened?; Screening for Pancreatic Cancer: Where Do We Stand?; Hereditary Colorectal Cancer: Genetics and Screening; Personalized Approach to Gastrointestinal Cancers; Screening for Colorectal Cancer; Screening for Prostate Cancer: Why the Controversy?; Gastric Cancer: East versus West-Is screening and early detection the difference?; and more!

The inhibition of angiogenesis is an effective mechanism of slowing down tumor growth and malignancies. The process of induction or pro-angiogenesis is highly desirable for the treatment of cardiovascular diseases, wound healing disorders, and more. Efforts to understand the molecular basis, both for inhibition and induction, have yielded fascinating results. Originally published by Bentham and now distributed by Elsevier, Anti-Angiogenesis Drug Discovery and Development, Volume 2 is an compilation of well-written reviews on various aspects of the anti-angiogenesis process. These reviews have been contributed by leading practitioners in drug discovery science and highlight the major developments in this exciting field in the last two decades. These reader-friendly chapters cover topics of great scientific importance, many of which are considered significant medical breakthroughs, making this book excellent reading both for the novice as well as for expert medicinal chemists and clinicians.

As bone marrow transplant treatments and chemotherapy develop, the population of neutropenic cancer patients is on the rise. These developments are allowing patients to live longer, but in recent years, they have also led to an increase in previously rare infections and syndromes, whose management is unfamiliar to the average healthcare professional. Infections in Neutropenic Cancer Patients is a crucial resource for medical students, residents, practitioners, health professionals, and researchers. It details the clinical presentation, diagnoses, and management of an array of common infections and syndromes specific to neutropenic cancer patients, including real scenarios accompanied by color photos and radiographic results. Chapters include step-by-step tutorials, access to clinical answers on diagnosis and treatment, and a tabulated summary of the key points.

The Guest Editors have assembled top key opinion leaders to provide current reviews on the multidisciplinary approach to the management of high-grade bladder cancer. Articles are devoted to fluorescence cystoscopy, confocal laser endomicroscopy, narrow band imaging; Novel therapeutic approaches for recurrent nonmuscle invasive bladder cancer; Trimodality therapy in bladder cancer; the data and the reality of perioperative chemotherapy in muscle invasive bladder cancer; radical transurethral resection alone, robotic or partial cystectomy or extended lymphadenectomy: Neoadjuvant paradigm for drug development in muscle invasive bladder cancer; Novel biomarkers to predict response and prognosis in localized bladder cancer; Immunotherapy in Advanced/Metastatic Urothelial Cancer ; and Adjuvant Chemotherapy in High Grade Upper Tract Urothelial Cancer.

This book provides the reader with a multidisciplinary approach that is state of the art and reflects input from the European Neuroendocrine Tumor Society and the North American Neuroendocrine Tumor Society. In particular, the text focuses on the pathophysiology of neuroendocrine tumors and includes a comprehensive review of the most recent developments in understanding the complex hormone and receptor signaling that is important for the future development of potent pharmacological treatments. The volume reviews the pathological grading and staging systems providing useful clinical information for the treating clinician as well as a useful reference for pathologists. The clinical management of neuroendocrine tumors is reviewed enabling the treating physician to understand the diagnostic approaches to differentiating the various types of neuroendocrine tumors. In addition, the treatments are reviewed in great detail and include novel radiological, surgical, and chemotherapeutic approaches. The reader will utilize this book as both a comprehensive and quick reference guide through the use of diagnostic and treatment algorithms. Written by international experts in their particular field of study, Management of Pancreatic Neuroendocrine Tumors will be of great value to medical oncologists, endocrinologists, gastroenterologists, pathologists, surgeons, and diagnostic and interventional radiologists.

This book is exceptional in presenting an interdisciplinary approach to the subject of human papillomavirus (HPV) infection in the context of head and neck cancer. Leading experts in the field discuss the epidemiology and molecular biology of HPV-positive head and neck squamous cell carcinoma, HPV testing, the nonsurgical and surgical treatment of HPV-positive tumors, predictive factors for outcome and quality of life, and ongoing trials on the effectiveness of vaccination in disease prevention. It also provides recommendations for testing, diagnosis treatment and vaccination. Otolaryngologists, head and neck surgeons, medical oncologists, radiation oncologists, molecular biologists and pathologists will find this book a valuable resource.

1. Prevention and Early Detection of Lung Cancer - Clinical Aspects.- 2. Smoking Prevention and Cessation.- 3. Clinical Pharmacology of Vitamin A and Retinoids.- 4. Early Lung Cancer Detection.- 5. Molecular Abnormalities in the Sequential Development of Lung Carcinoma.- 6. Application of In Situ PCR and In Situ Hybridization to the Characterization of Lung Cancers.- 7. Tumor Stroma Formation in Lung Cancer.- 8. Tumor Angiogenesis: Basis for New Prognostic Factors and New Anticancer Therapies.- 9. Cell Cycle Regulators and Mechanisms of Growth Control Evasion in Lung Cancer.- 10. Molecular Genetics of Lung Cancer.- 11. Neuropeptides, Signal Transduction and Small Cell Lung Cancer.- 12. In Vitro Analysis of Bombesin/Gastrin-Releasing Peptide Receptor (bb2) Ligand Binding and G-Protein Coupling.- 13. DNA Methylation Changes in Lung Cancer.- 14. K-ras Mutations as Molecular Markers of Lung Cancer.- 15. Sheep Lung Adenomatosis: A Model of Virally Induced Lung Cancer.- 16. Retinoic Acid Receptor ss An Exploration of its Role in Lung Cancer Suppression and its Potential in Cancer Prevention.- 17. Cytochrome P450 Polymorphisms: Risk Factors for Lung Cancer?.- 18. Glutathione S-Transferases and Lung Cancer Risk.- 19. The p53 Tumor Suppressor Gene in Lung Cancer: From Molecular to Serological Diagnosis.- 20. Endoscopic Localization of Preneoplastic Lung Lesions.- 21. Antigen Retrieval Improves hnRNP A2/B1 Immunohisto-chemical Localization in Premalignant Lesions of the Lung.- 22. Molecular Pathological Mechanisms in NSCLC and the Assessment of Individuals with a High Risk of Developing Lung Cancer.- 23. Chemoprevention of Lung Cancer.- 24. Regional Delivery of Retinoids: A New Approach to Early Lung Cancer Intervention.- 25. Natural Inhibitors of Carcinogenesis.- 26. Gene Delivery to Airways.- 27. Lung Cancer Prevention: The Point of View of a Public Health Epidemiologist.- 28. Biomarkers as Intermediate Endpoints in Chemoprevention Trials: Biological Basis of Lung Cancer Prevention.- 29. Biological Tools for Mass Screening.- 30. Optimization of the Use of Biological Samples for the Prospective Evaluation of Preneoplastic Lesions.

Cancer Treatment and the Ovary: Clinical and Laboratory Analysis of Ovarian Toxicity provides the reader with a basic understanding on how the ovary is adversely impacted by cancer treatment, an essential foundational knowledge for this rapidly-developing field. The book describes both the clinical and laboratory approaches to discovering the potentially adverse effects of cancer treatment on the ovary, also laying out possible preventative approaches and future directions for the field. Clinicians working in the field of reproductive biology and oncology will find an essential reference that provides the necessary tools to assess the reproductive toxicological effects of cancer treatments.

The molecular and genetic signatures of cancer are represented in the peripheral circulation and other body fluids, giving rise to the "liquid biopsy" concept. This new paradigm of molecular profiling of cancer cells offers several advantages over traditional tissue biopsy. It is convenient, noninvasive, conforms to current clinical practice, enables real time disease monitoring and the study of tumor evolution, can easily be sampled multiple times, and this sample is more representative of the heterogeneous cancer cells than biopsy sampling. Indeed, all aspects of cancer molecular genetic information, stemming from DNA (both nuclear and mitochondria), RNA (coding and noncoding), peptides and proteins, metabolites and lipids are present in body fluids as free, cell surface bound or enclosed in membrane vesicles, and are being harnessed for disease management. Additionally, circulating tumor, and tumor stem cells provide prognostic information, and also enable the study of the intricate molecular processes associated with metastasis and drug resistance. This treatise deals with the general principles of the molecular pathology of cancer, and its associated imprints in circulation. The transitional process from discovery, prototype development, translational research, to product development can be complex and costly. The critical path to biomarker development and qualification for successful use in drug development is detailed herein as well. This book is of interest to Cancer Researchers, Oncologists, Clinicians, Surgeons, Medical Students, Nurses, Diagnostic Laboratories, and Pharmaceutical Industries.

This volume provides a broad spectrum of research models, techniques, and protocols. Chapters are divided into sections providing detailed information on the background and context for the chosen topic of interest, a list of the necessary materials and reagents needed for each topic, as well as the step-by-step laboratory protocols and methodologies for the successful and reproducible execution of each topic. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and practical, Inflammation and Cancer: Methods and Protocols aims to provide information to students and researchers at all levels of experience for further study into this vital field.

The Editors for this issue of Otolaryngologic Clinics, Dr George Wanna and Dr Matthew Luke Carlson, envisioned a publication that reviews the evaluation and management of common ear and lateral skull base tumors. Intended audience includes Otologists, Neurotologists, General otolaryngologists and Neurosurgeons alike. The development of management of lateral skull base tumors has been rapid, in the past 40 years there has been a tremendous shift toward conservative therapy for benign lesions. Focused chapters review specific pathologies plus a chapter focused on stereotactic radiotherapy. Topics written by reputed leaders in the field of Otology and skull base tumors include: Imaging of temporal bone lesions; Squamous cell carcinoma of the temporal bone; Glomus tympanicum; Adenomatous tumors of the middle ear; Intralabyrinthine schwannomas; Vestibular schwannoma; Neurofibromatosis2 (including ABI and CI); Non-schwannoma tumors of the CPA; Glomus jugulare; Endolymphatic sac tumors; Non-paraganglioma jugular foramen tumors; Primary tumors of the facial nerve; Cholesterol granuloma and other petrous apex lesions; Stereotactic radiosurgery for tumors of the lateral skull base; Pediatric temporal bone malignancy; and Historical perspective on evolution in management of lateral skull base tumors.

This issue concentrates on the current evidence and the collected experience of pediatric oncologists who care for cancer patients. The individual articles will provide the general pediatrician with a comprehensive primer on diagnosing and managing various types of cancers in the child with cancer. A cancer diagnosis is no longer a death sentence, so management and monitoring is very important and covered in every article.

This book offers a complete overview on non colorectal non neuroendocrine (NCRNNE) liver metastases and describes in detail the currently available therapies. Each chapter focuses on the treatment of metastases from a particular primary malignancy and also provides valuable information on incidence, natural history and diagnosis. NCRNNE liver metastases are rare entities compared with colorectal and neuroendocrine metastases, for which the treatments are well codified. While more publications have appeared on the topic in recent years, an in-depth study has to date been lacking. Furthermore, most published series are insufficiently comparable as they comprise patients with NCRNNE hepatic metastases from a variety of primary malignancies and consequently overlook differences in tumor behavior, frequency of isolated hepatic metastases, response to neoadjuvant or adjuvant therapy and interval between diagnosis of the primary tumor and the liver metastases. This book, with its more specific approach, will serve not only as an up-to-date guide to diagnosis and treatment but also as a reference on which to base future studies.

This text highlights the endogenous regenerative potential of the central nervous system in neonates and juveniles and discusses possible ways it might be manipulated for medical purposes. The first section provides a descriptive summary of the salient steps of human brain development with a discussion of comparisons with other mammalian brains. It also provides a historical perspective on our understanding of ongoing brain development throughout the lifespan and serve to introduce the concept of brain plasticity following injury. The second part is devoted to the endogenous reparative potential of the brain, including its limitations, and articles focusing on defined pathologies (e.g. anoxia/hypoxia, epilepsy, traumatic brain injury and stress) in animal models and in humans pinpoint eventual ways these pathologies might be manipulated. The third and final focuses on the "dark side" of stem cells for brain repair or of the manipulation of spontaneous adaptive events after injury (e.g. genomic instability, sensitization to cancerous transformation and defective neural networks).

This issue of Surgical Oncology Clinics of North America, edited by Dr. Lawrence Wagman, is devoted to Hepatocellular Cancer, Cholangiocarcinoma, and Metastatic Tumors of the Liver. Articles in this issue include: Epidemiology of Hepatomas; Risk Modeling: disease prevalence, outcome from treatment; Imaging; Resection techniques; Ablation techniques; Complications of interventions; Trans-arterial chemo-embolization (TACE); Continuous hepatic artery infusion (CHAI); Selective interstitial radiation therapy (SIRT) and External beam radiation therapy (EBRT); Systemic chemotherapy of HCC and Cholangiocarcinoma; and Systemic chemotherapy and CRC metastases.